Neovacs : GRANTED 1.8 MILLION EURO IN RESEARCH TAX CREDIT

 PRESS RELEASE ·  PRESS RELEASE  · PRESS RELEASE

NEOVACS GRANTED 1.8 MILLION EURO IN RESEARCH TAX CREDIT

Paris and Boston,  May 13, 2015 - NEOVACS (Alternext Paris : ALNEV), a leader in active immunotherapies for the treatment of autoimmune diseases, today announced that it has received €1.8 million in research tax credit for R&D expenses incurred in 2014.

The funds received through the tax credit will be used to fund the clinical and pre-clinical development of Neovacs' therapeutic vaccines portfolio.

"We are actively pursuing the clinical development of IFNalpha-Kinoid in lupus and dermatomyositis, while carefully controlling our expenditures. The phase IIb clinical trial of IFNalpha-Kinoid in lupus will be initiated in the coming months in Europe, Asia and Latin America; it will be followed by a phase I/II trial in the U.S. in early 2016" commented Miguel Sieler, Chief Executive Officer of Neovacs.

The anticipated paiement of the research tax credit for 2014 was obtained through a pre-financing mechanism put in place with NEFTYS Conseil.  

About Neovacs
Created in 1993, Neovacs is today a leading biotechnology company focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune and/or inflammatory diseases. On the basis of the company's proprietary technology for inducing a polyclonal immune response (covered by five patent families that potentially run until 2032) Neovacs is focusing its clinical development efforts on IFNalpha-Kinoid, an immunotherapy being developed for the indication of lupus and dermatomyositis. Neovacs is also conducting preclinical development works on other therapeutic vaccines in the fields of auto-immune diseases, oncology and allergies. The goal of the Kinoid approach is to enable patients to have access to safe treatments with efficacy that is sustained in these life-long diseases.

For more information on Neovacs, please visit www.neovacs.fr

Contacts
                                                              
NEOVACS - Investor Relations                                      
Nathalie Trépo                                                                   
+33 (0)1 53 10 93 00                                                       
ntrepo@neovacs.com

Investor Relations / Financial Communications - NewCap
Valentine Brouchot / Pierre Laurent
+33 (0)1 44 71 94 94
theradiag@newcap.fr